Newsletter | November 4, 2020

11.04.20 -- New Podcast Episodes: CAR T Therapy Cost Control, Gap Analysis, And More

 
     
 
 
 
 
Listen Now: Our Latest Podcast Episodes
 
 

Check out the latest from Business of Biotech, Biotech with the Bozenhardts, and Life Science Connect. As a member of the Life Science Connect community you have access to content beyond our weekly newsletters, including our podcast series. Don’t forget to subscribe so that you never miss an episode!

 
 
     
 
THE PODCAST FOR LEADERS OF EMERGING BIOPHARMA
 
 
 

 
 
Off-The-Shelf CAR T-Cell Therapy With John McKearn, Ph.D.
 
 

Find out what drove John McKearn, Ph.D. and CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-cell leukemias and lymphomas, acute myeloid leukemia, and multiple myeloma.

 
 
CAR T Therapy Cost Control With Laurence Cooper, M.D., Ph.D.
 
 

Controlling the cost of personalized medicine: We go behind the scenes of the effort to build a system that simplifies production and reduces the cost of nonviral T-cell therapies with Ziopharm Oncology CEO Laurence Cooper, M.D., Ph.D.

 
 
Gap Analysis With Dr. Pablo Valenzuela And Cristián Hernández-Cuevas
 
 

We're joined by biopharma pioneer Dr. Pablo Valenzuela and rising star Cristián Hernández-Cuevas, both of Andes Biotechnologies, for a candid discussion on biopharma's compute power revolution, gap analyses, next steps for emerging biopharma, and what's driving growth in South America.

 
 
     
 
BIOTECH FACILITY DESIGN PODCAST
 
 

 
 
 

Herman and Erich Bozenhardt have a collective 55 years of bioprocess facilities design and equipment experience, and they’re here to share it all in our fresh Bioprocess with the Bozenhardts podcast series.

 
 
     
 
THE LATEST AND GREATEST FROM LIFE SCIENCE CONNECT
 
 

 
 
The Golden Age Of Biosimilars? Really?
 

It was only a little more than a year ago when the phrase “throw in the towel” was being used in reference to the biosimilars industry. Now, some say we’re in the “golden age” of biosimilars. Anna Rose Welch tries to explain why the big flip. 

 
 
An Executive Order And PhRMA’s Response Spur A Debate
 

Our guest, Outsourced Pharma chief editor Louis Garguilo, talks about the response from readers — and PhRMA — to his editorial, “Is PhRMA’s White House Rebuttal Acceptable?”